美国宫颈癌筛查女性HPV疫苗型别流行率下降:直接与群体保护证据
研究基于Kaiser Permanente Northwest 2007年及疫苗时代(2012-2013、2015-2016)20-29岁宫颈癌筛查女性的细胞学标本,检测37种HPV型别。结果显示疫苗型HPV(6/11/16/18)流行率在20-24岁女性中从2007年13.1%降至2015-2016年2.9%(PR=0.22,95%CI 0.17-0.29),接种与未接种者均下降,提示直接与群体保护效应。
要点
- 20-24岁女性疫苗型HPV流行率从13.1%降至2.9%(PR=0.22),9-10年内下降78%。
- 25-29岁女性疫苗型HPV流行率从8.1%降至5.0%(PR=0.62),下降38%。
- 未接种女性疫苗型HPV亦下降,提示群体保护效应。
核心结论
- 引入HPV疫苗9-10年内,20-24岁女性疫苗型HPV流行率下降78%,25-29岁下降38%。
- 接种与未接种女性疫苗型HPV均下降,提示直接与群体保护效应。
研究设计与样本
- 研究检测2007年及疫苗时代(2012-2013、2015-2016)Kaiser Permanente Northwest 20-29岁宫颈癌筛查女性细胞学标本的HPV型别。
- 采用L1通用PCR及杂交法检测37种HPV型别,包括四价疫苗型别(HPV 6/11/16/18)。
主要发现
- 20-24岁女性中,2012-2013和2015-2016分别有44%和64%有≥1剂疫苗接种史;疫苗型HPV流行率从2007年13.1%降至2015-2016年2.9%(PR=0.22;95%CI 0.17-0.29)。
- 2015-2016年20-24岁接种女性疫苗型HPV流行率为1.3%(PR=0.10;95%CI 0.06-0.16),未接种女性为5.8%(PR=0.45;95%CI 0.33-0.61)。
- 25-29岁女性中,2012-2013和2015-2016分别有21%和32%有≥1剂疫苗接种史;疫苗型HPV流行率从2007年8.1%降至2015-2016年5.0%(PR=0.62;95%CI 0.50-0.78)。
- 疫苗时代HPV 31流行率较2007年降低;非疫苗型高危HPV流行率在疫苗时代较疫苗前时代升高,但2015-2016与2012-2013相比无升高。
临床怎么用
- 筛查中可监测疫苗型HPV流行率变化以评估HPV疫苗接种的直接与群体效应。
- 未接种女性疫苗型HPV亦下降,提示群体保护可惠及未接种人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) vaccine has been recommended in the United States since 2006 for routine vaccination of girls at age 11-12 years and through age 26 years for women not previously vaccinated. Changes in vaccine-type HPV (VT) prevalence can be used to evaluate vaccine impact, including herd effects. METHODS: We determined type-specific HPV in cytology specimens from women aged 20-29 years screened for cervical cancer at Kaiser Permanente Northwest in 2007 and in two vaccine era periods: 2012-2013 and 2015-2016. Detection and typing used L1 consensus PCR with hybridization for 37 types, including quadrivalent vaccine types (HPV 6/11/16/18). RESULTS: Among 20-24 year-olds in 2012-2013 and 2015-2016, 44% and 64% had a history of ≥1-dose vaccination. VT prevalence decreased from 13.1% in 2007 to 2.9% in 2015-2016 (prevalence ratio [PR] = 0.22; 95% confidence interval [CI] 0.17-0.29). HPV 31 prevalence was also lower in the vaccine periods compared with 2007. VT prevalence in 2015-2016 among 20-24 year-olds was lower in both vaccinated, 1.3% (PR = 0.10; 95% CI 0.06-0.16), and unvaccinated women, 5.8% (PR = 0.45; 95% CI 0.33-0.61). Among 25-29 year-olds, 21% and 32% had a history of ≥1-dose vaccination. VT prevalence decreased from 8.1% in 2007 to 5.0% in 2015-2016 (PR = 0.62; 95% CI 0.50-0.78). Non-VT high risk prevalence was higher in the vaccine periods compared with the pre-vaccine era in both age groups, however, not in 2015-2016 compared with 2012-2013. CONCLUSION: Within 9-10 years of vaccine introduction, VT prevalence decreased 78% among 20-24 year-olds and 38% in 25-29 year-olds. There were declines in both vaccinated and unvaccinated women, showing evidence of direct and herd protection.
引用
- Markowitz LE, Naleway AL, Lewis RM, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine. 2019. PMID: 31160099. doi:10.1016/j.vaccine.2019.04.099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。